Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Cash from Operations (2017 - 2025)

Historic Cash from Operations for Arcus Biosciences (RCUS) over the last 9 years, with Q3 2025 value amounting to -$97.0 million.

  • Arcus Biosciences' Cash from Operations fell 47307.69% to -$97.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$462.0 million, marking a year-over-year decrease of 19240.51%. This contributed to the annual value of -$170.0 million for FY2024, which is 4444.44% up from last year.
  • Latest data reveals that Arcus Biosciences reported Cash from Operations of -$97.0 million as of Q3 2025, which was down 47307.69% from -$133.0 million recorded in Q2 2025.
  • Arcus Biosciences' Cash from Operations' 5-year high stood at $654.0 million during Q1 2022, with a 5-year trough of -$133.0 million in Q2 2025.
  • Its 5-year average for Cash from Operations is -$34.5 million, with a median of -$70.0 million in 2022.
  • In the last 5 years, Arcus Biosciences' Cash from Operations skyrocketed by 108618.73% in 2022 and then tumbled by 650000.0% in 2025.
  • Quarter analysis of 5 years shows Arcus Biosciences' Cash from Operations stood at -$61.9 million in 2021, then fell by 13.03% to -$70.0 million in 2022, then fell by 25.71% to -$88.0 million in 2023, then dropped by 13.64% to -$100.0 million in 2024, then grew by 3.0% to -$97.0 million in 2025.
  • Its last three reported values are -$97.0 million in Q3 2025, -$133.0 million for Q2 2025, and -$132.0 million during Q1 2025.